Skip to Content
Merck
CN

Key Documents

View All Documentation

SMB00958

N-Desmethyl imatinib

research grade, ≥95%

Synonym(s):

N-(4-Methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-4-(piperazin-1-ylmethyl)benzamide, N-Desmethylimatinib, N-[4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(1-piperazinylmethyl)benzamide, CGP74588, Desmethyl Gleevec, Norimatinib

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C28H29N7O
CAS Number:
404844-02-6
Molecular Weight:
479.58
UNSPSC Code:
12352205
NACRES:
NA.77
Assay:
≥95%
Form:
solid
Quality level:
200
Storage condition:
(Tightly closed. Dry. Keep in a well -ventilated place. Keep locked up or in an area accessible only to qualified or authorized persons.)
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

biological source

synthetic

Quality Level

200

assay

≥95%

form

solid

mol wt

479.58 g/mol

storage condition

(Tightly closed. Dry. Keep in a well -ventilated place. Keep locked up or in an area accessible only to qualified or authorized persons.)

technique(s)

HPLC: suitable

solubility

ethanol: 0.20 mg/mL, DMF: 16 mg/mL

storage temp.

2-8°C

SMILES string

N5(CCNCC5)Cc1ccc(cc1)C(=O)Nc2cc(c(cc2)C)Nc3nc(ccn3)c4cnccc4

InChI

1S/C28H29N7O/c1-20-4-9-24(17-26(20)34-28-31-12-10-25(33-28)23-3-2-11-30-18-23)32-27(36)22-7-5-21(6-8-22)19-35-15-13-29-14-16-35/h2-12,17-18,29H,13-16,19H2,1H3,(H,32,36)(H,31,33,34)

InChI key

BQQYXPHRXIZMDM-UHFFFAOYSA-N

General description

N-Desmethyl imatinib is a pharmacologically active metabolite of imatinib with long elimination half-life. Imatinib is metabolized to N-desmethyl imatinib by CYPs 3A4 and 2C8.

Application

Application: Metabolomics research

Other Notes

For additional information on our range of Biochemicals, please complete this form.

pictograms

Health hazard
GHS08

signalword

Danger

Hazard Classifications

Carc. 2 - Lact. - Muta. 2 - Repr. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000515067
0000515067
0000267181
0000267181
0000113576

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Muhammad Suleman Khan et al.
Xenobiotica; the fate of foreign compounds in biological systems, 46(3), 278-287 (2015-07-15)
1. Imatinib is metabolized to N-desmethyl imatinib by CYPs 3A4 and 2C8. The effect of CYP2C8*3 genotype on N-desmethyl imatinib formation was unknown. 2. We examined imatinib N-demethylation in human liver microsomes (HLMs) genotyped for CYP2C8*3, in CYP2C8*3/*3 pooled HLMs
Hans-Peter Gschwind et al.
Drug metabolism and disposition: the biological fate of chemicals, 33(10), 1503-1512 (2005-07-12)
Imatinib mesylate (GLEEVEC, GLIVEC, formerly STI571) has demonstrated unprecedented efficacy as first-line therapy for treatment for all phases of chronic myelogenous leukemia and metastatic and unresectable malignant gastrointestinal stromal tumors. Disposition and biotransformation of imatinib were studied in four male
Yuji Mukai et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1137, 121928-121928 (2019-12-27)
Therapeutic drug monitoring is important in patients taking BCR-ABL and Bruton's tyrosine kinase inhibitors (TKIs). Some TKI active metabolites with long elimination half-lives, such as dihydrodiol ibrutinib (DHI), N-desmethyl imatinib (N-DI), and N-desmethyl ponatinib (N-DP), have been characterized, indicating that

Global Trade Item Number

SKUGTIN
SMB00958-25MG04065265200288
SMB00958-5MG04065265200295